Immunocore announces closing of $75.0 Million Series C round
January 11, 2021 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...